Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)
December 01, 2023 09:00 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update
November 13, 2023 16:15 ET
|
Cingulate Inc.
Phase 3 Adult Efficacy and Safety Trial Data Presented at Psych Congress Cingulate Closed a $4M Public Offering $5.8M of Debt Converted into CING Equity KANSAS CITY, Kan., Nov. 13, 2023 (GLOBE...
Cingulate to Host CNS Key Opinion Leader Panel in New York City
October 17, 2023 14:22 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate Inc. to Present at the LD Micro Main Event XVI
September 21, 2023 13:30 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate Announces Closing of $4.0 Million Public Offering
September 13, 2023 16:15 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary Precision...
Cingulate Announces Pricing of $4.0 Million Public Offering
September 11, 2023 09:22 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary...
Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
September 11, 2023 06:00 ET
|
Cingulate Inc.
CTx-1301 Demonstrated Clinically Meaningful Improvements in Permanent Product Measure of Performance (PERMP) and Clinical Global Impression Scale (CGI-S) Scores, with Investigators Observing Trend...
Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium
September 08, 2023 16:31 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (Cingulate), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023
September 05, 2023 08:00 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
August 14, 2023 16:15 ET
|
Cingulate Inc.
Werth Family Investment Associates Provides Additional Capital InvestmentPhase 3 Adult Efficacy and Safety Trial of CTx-1301 Data ReleasedCTx-1301 Phase 3 Pediatric and Adolescent Studies Underway ...